Skip to content

SmallCap Round Up: Sopheon, Real Good Food, Ondine Biomedical


London’s AIM Index had another morning of gains, helped by that tamer inflation data published this morning. By 2.30pm the all share was up just under two points at 680.57.

  • Sopheon +88%
  • Real Good Food +50%
  • Ondine Biomedical +19%
  • Velocys -70%
  • Kore Potash -27%

Sopheon [LON:SPE] posted an update this morning covering off a possible cash offer that had been made for the business, sitting some 88% higher at 2.30pm. Key terms have been reached in a deal worth £10 per share, with the stock now trading at £9.40. Due diligence has been completed although the company notes that this still doesn’t constitute a firm intention to make a bid.

Real Good Food [LON:RGD] was in second place, up 50% at copy time following a trading update. After a slow start to the year, momentum is building and this is filtering through to higher revenues and significantly lower losses. The next target is to get the company to a sustainable annual EBITDA level of £4m.

Ondine Biomedical [LON:OBI] gets the notable mention, having added 19%. The company announced this morning that use of its Steriwave photodisinfection service was being expanded by healthcare providers in Alberta, Canada, whilst trials are now underway with an NHS provider in Yorkshire.

Velocys [LON:VLS] was the biggest faller, down 69% by copy time. A funding update this morning noted that terms for any new capital were likely to be at levels somewhat disadvantageous to shareholders, with the market clearly spooked by the news.

Kore Potash [LON:KP2] was in second to last place at 2.30pm, down 27%. That follows news of a funding round, with the shares being marked back to reflect the offer discount. That includes a $750k buy in from the chairman which ought to offer some confidence with the proceeds used to further advance work for the delivery of the Kola potash project.

Looking for great investing ideas? Sign up to our free newsletter.

This article does not constitute investment advice. Make sure you do your own research or consult a professional advisor.

'How to' Guides

Our latest in-depth company reports

Detailed reviews of selected companies and investment trusts.

On the podcast

Sign up for great investing stock tips

Thanks to our Site Partners

Our partners are established, regulated businesses and we are grateful for their support.

FP Markets
CME Group
Back To Top